AR068877A1 - Derivados heterociclicos de imidazol - Google Patents
Derivados heterociclicos de imidazolInfo
- Publication number
- AR068877A1 AR068877A1 ARP080104492A ARP080104492A AR068877A1 AR 068877 A1 AR068877 A1 AR 068877A1 AR P080104492 A ARP080104492 A AR P080104492A AR P080104492 A ARP080104492 A AR P080104492A AR 068877 A1 AR068877 A1 AR 068877A1
- Authority
- AR
- Argentina
- Prior art keywords
- carbon atoms
- alkyl
- amino
- independently selected
- alkoxy
- Prior art date
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 75
- 125000000217 alkyl group Chemical group 0.000 abstract 39
- 125000003545 alkoxy group Chemical group 0.000 abstract 15
- 229910052736 halogen Inorganic materials 0.000 abstract 12
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 11
- 150000002367 halogens Chemical class 0.000 abstract 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 9
- 229910052799 carbon Inorganic materials 0.000 abstract 9
- 125000000623 heterocyclic group Chemical group 0.000 abstract 9
- 125000003118 aryl group Chemical group 0.000 abstract 8
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 6
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 5
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 150000003462 sulfoxides Chemical class 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
- -1 cyano, amino Chemical group 0.000 abstract 2
- 125000004122 cyclic group Chemical group 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 2
- 125000004001 thioalkyl group Chemical group 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 1
- 102100034134 Activin receptor type-1B Human genes 0.000 abstract 1
- 101710173011 Activin receptor type-1B Proteins 0.000 abstract 1
- 101100173726 Arabidopsis thaliana OR23 gene Proteins 0.000 abstract 1
- 101000712674 Homo sapiens TGF-beta receptor type-1 Proteins 0.000 abstract 1
- 229910003827 NRaRb Inorganic materials 0.000 abstract 1
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 abstract 1
- IUHFWCGCSVTMPG-UHFFFAOYSA-N [C].[C] Chemical group [C].[C] IUHFWCGCSVTMPG-UHFFFAOYSA-N 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 1
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000000565 sulfonamide group Chemical group 0.000 abstract 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07118726 | 2007-10-17 | ||
| EP08151336 | 2008-02-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR068877A1 true AR068877A1 (es) | 2009-12-09 |
Family
ID=39944334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104492A AR068877A1 (es) | 2007-10-17 | 2008-10-15 | Derivados heterociclicos de imidazol |
Country Status (23)
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8343966B2 (en) * | 2008-01-11 | 2013-01-01 | Novartis Ag | Organic compounds |
| CN102159559A (zh) * | 2008-07-18 | 2011-08-17 | 赛诺菲-安万特 | 新型咪唑并[1,2-a]吡啶衍生物、其制备方法、其作为药物的用途、其药物组合物和新型用途特别是作为MET抑制剂的新型用途 |
| FR2945806B1 (fr) * | 2009-05-19 | 2013-04-05 | Sanofi Aventis | Nouveaux derives imidazo[1,2-a]pyridine,procede de preparation,medicaments,compositions pharmaceutiques et utilisation notamment comme inhibiteurs de met |
| CA2760778A1 (en) * | 2009-05-13 | 2010-11-18 | Amgen Inc. | Heteroaryl compounds as pikk inhibitors |
| EP2454262B1 (en) * | 2009-07-15 | 2014-05-14 | Abbott Laboratories | Pyrrolopyrazine inhibitors of kinases |
| UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
| WO2011146287A1 (en) | 2010-05-20 | 2011-11-24 | Takeda Pharmaceutical Company Limited | Pyrazolo[4,3-b]pyridine-7-amine inhibitors of alk5 |
| CN102443009B (zh) * | 2010-09-30 | 2014-04-16 | 山东轩竹医药科技有限公司 | 并环激酶抑制剂 |
| EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
| PH12013502695A1 (en) * | 2011-07-01 | 2019-06-14 | Bayer Ip Gmbh | Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors |
| EP2554544A1 (en) | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1h)-one derivatives as jak inhibitors |
| ES2790358T3 (es) | 2011-12-28 | 2020-10-27 | Global Blood Therapeutics Inc | Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular |
| SI3738434T1 (sl) * | 2011-12-28 | 2024-01-31 | Global Blood Therapeutics, Inc. | Vmesne spojine za pridobivanje substituiranih benzaldehidnih spojin in postopki njihove uporabe pri povečanju oksigenacije tkiv |
| GB201205669D0 (en) * | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| US10280168B2 (en) | 2012-03-30 | 2019-05-07 | Agency For Science, Technology And Research | Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof |
| BR112014030812B1 (pt) | 2012-06-13 | 2022-11-08 | Incyte Holdings Corporation | Compostos tricíclicos substituídos como inibidores de fgfr, seus usos, composição farmacêutica e método para inibir uma enzima fgfr |
| US9738636B2 (en) | 2012-09-28 | 2017-08-22 | Vanderbilt University | Fused heterocyclic compounds as selective BMP inhibitors |
| US9981939B2 (en) | 2013-03-15 | 2018-05-29 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| EP2970196B1 (en) | 2013-03-15 | 2020-11-25 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| SG11201507453VA (en) | 2013-03-15 | 2015-10-29 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US20140274961A1 (en) | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| ME03015B (me) | 2013-04-19 | 2018-10-20 | Incyte Holdings Corp | Biciklični heterocikli kao fgfr inhibitori |
| WO2015031285A1 (en) * | 2013-08-27 | 2015-03-05 | Global Blood Therapeutics, Inc. | Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| DK3102208T4 (da) | 2014-02-07 | 2024-08-26 | Global Blood Therapeutics Inc | Krystallinsk polymorph af den frie base af 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyd |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
| US10836742B2 (en) | 2015-08-11 | 2020-11-17 | Neomed Institute | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals |
| US10501438B2 (en) | 2015-08-11 | 2019-12-10 | Neomed Institute | Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals |
| ES2904258T3 (es) | 2015-08-12 | 2022-04-04 | Neomed Inst | Bencimidazoles sustituidos, su preparación y su uso como productos farmacéuticos |
| WO2017066876A1 (en) | 2015-10-21 | 2017-04-27 | Neomed Institute | Substituted imidazopyridines, their preparation and their use as pharmaceuticals |
| ES3039236T3 (en) | 2015-12-04 | 2025-10-20 | Global Blood Therapeutics Inc | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| US10519151B2 (en) | 2016-01-28 | 2019-12-31 | Neomed Institute | Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals |
| TWI663160B (zh) | 2016-05-12 | 2019-06-21 | 全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
| US11352328B2 (en) | 2016-07-12 | 2022-06-07 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus |
| WO2018053126A1 (en) * | 2016-09-14 | 2018-03-22 | Vanderbilt University | Inhibition of bmp signaling, compounds, compositions and uses thereof |
| TW202332423A (zh) | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| KR20200115620A (ko) | 2018-01-29 | 2020-10-07 | 메르크 파텐트 게엠베하 | Gcn2 억제제 및 이의 용도 |
| EP3765460A1 (en) | 2018-03-14 | 2021-01-20 | Vanderbilt University | Inhibition of bmp signaling, compounds, compositions and uses thereof |
| TW201946630A (zh) | 2018-05-04 | 2019-12-16 | 美商英塞特公司 | Fgfr抑制劑之鹽 |
| SG11202010636VA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Solid forms of an fgfr inhibitor and processes for preparing the same |
| US11014884B2 (en) | 2018-10-01 | 2021-05-25 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
| US12419865B2 (en) | 2018-12-06 | 2025-09-23 | Arisan Therapeutics Inc. | Compounds for the treatment of arenavirus infection |
| IL318278A (en) * | 2018-12-20 | 2025-03-01 | Incyte Corp | Imidazopyridazine and imidazopyridine compounds and their use |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| JP7300057B2 (ja) * | 2019-07-26 | 2023-06-28 | シージーンテック （スーチョウ， チャイナ） カンパニー リミテッド | Ｆｇｆｒとｖｅｇｆｒ二重阻害剤としてのピリジン誘導体 |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CA3153456A1 (en) | 2019-10-02 | 2021-04-08 | Stefanie Fluckiger-Mangual | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| AU2020395185A1 (en) | 2019-12-04 | 2022-06-02 | Incyte Corporation | Derivatives of an FGFR inhibitor |
| CN111116582B (zh) * | 2019-12-18 | 2022-07-29 | 大连大学 | 一种mGluR2拮抗剂 |
| EP4076456B1 (en) * | 2019-12-19 | 2024-05-01 | Université de Strasbourg | Sigma-1 receptor ligands and therapeutic uses thereof |
| CN115052663A (zh) | 2020-01-08 | 2022-09-13 | 辛瑟斯治疗股份有限公司 | Alk5抑制剂缀合物及其用途 |
| WO2021146424A1 (en) * | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021147699A1 (zh) * | 2020-01-21 | 2021-07-29 | 四川科伦博泰生物医药股份有限公司 | 吡啶并杂环类化合物、其制备方法及用途 |
| IL298248A (en) | 2020-06-12 | 2023-01-01 | Incyte Corp | Imidazopyridazine compounds and their use |
| US20230226057A1 (en) * | 2020-06-25 | 2023-07-20 | Tolremo Therapeutics Ag | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease |
| WO2021260111A1 (en) | 2020-06-25 | 2021-12-30 | Tolremo Therapeutics Ag | Combination of a cbp/p300 bromodomain inhibitor and a kras inhibitor for the treatment of cancer |
| JP7686741B2 (ja) | 2020-07-15 | 2025-06-02 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ａｌｋ５阻害剤としてのピリダジニルアミノ誘導体 |
| EP4182322B1 (en) | 2020-07-15 | 2024-04-24 | Chiesi Farmaceutici S.p.A. | Pyrido oxazine derivatives as alk5 inhibitors |
| JP2023533850A (ja) | 2020-07-15 | 2023-08-04 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | Ａｌｋ５阻害剤としてのピリドオキサジンアミノ誘導体 |
| WO2022136221A1 (en) | 2020-12-23 | 2022-06-30 | Chiesi Farmaceutici S.P.A. | Pyrido oxazine derivatives as alk5 inhibitors |
| KR20230134545A (ko) * | 2021-01-26 | 2023-09-21 | 씨젠테크 (쑤저우, 차이나) 컴퍼니 리미티드 | 메틸피라졸로로 치환된 피리도 이미다졸계 화합물의결정형 및 이의 제조방법 |
| EP4323405A1 (en) | 2021-04-12 | 2024-02-21 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| TW202313611A (zh) | 2021-06-09 | 2023-04-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之三環雜環 |
| AR127108A1 (es) | 2021-09-21 | 2023-12-20 | Chiesi Farm Spa | Derivados de amino piridazinilo como inhibidores de alk5 |
| AU2022359801A1 (en) | 2021-10-04 | 2024-02-01 | Forx Therapeutics Ag | Parg inhibitory compounds |
| WO2023208986A1 (en) | 2022-04-27 | 2023-11-02 | Chiesi Farmaceutici S.P.A. | Imidazole derivatives as alk5 inhibitors |
| AU2023355735A1 (en) | 2022-10-03 | 2025-04-03 | Forx Therapeutics Ag | Parg inhibitory compound |
| WO2024209035A1 (en) | 2023-04-05 | 2024-10-10 | Forx Therapeutics Ag | Parg inhibitory compounds |
| WO2024258967A1 (en) | 2023-06-13 | 2024-12-19 | Synthis Therapeutics, Inc. | Anti-cd5 antibodies and their uses |
| WO2025073870A1 (en) | 2023-10-03 | 2025-04-10 | Forx Therapeutics Ag | Parg inhibitory compound |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1016489B (it) | 1974-03-18 | 1977-05-30 | Isf Spa | Inalatore |
| PT995457E (pt) | 1995-12-07 | 2004-07-30 | Jago Res Ag | Bocal para um inalador para a distribuicao reiterada doseadamente de um po farmacologicamente seco |
| PT883415E (pt) | 1996-02-21 | 2002-10-31 | Schering Corp | Inalador para medicacao em po |
| GB9927687D0 (en) * | 1999-11-23 | 2000-01-19 | Merck Sharp & Dohme | Therapeutic agents |
| DE10117183A1 (de) * | 2001-04-05 | 2002-10-10 | Gruenenthal Gmbh | Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel |
| ATE402164T1 (de) * | 2001-04-26 | 2008-08-15 | Eisai R&D Man Co Ltd | Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon |
| GB0128499D0 (en) | 2001-11-28 | 2002-01-23 | Merck Sharp & Dohme | Therapeutic agents |
| AU2003241326B2 (en) * | 2002-05-02 | 2008-05-01 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO2004013135A1 (en) * | 2002-07-31 | 2004-02-12 | Smithkline Beecham Corporation | 2-phenylpyridin-4-yl derivatives as alk5 inhibitors |
| GB0217783D0 (en) * | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Compounds |
| GB2407042B (en) | 2003-10-17 | 2007-10-24 | Vectura Ltd | Inhaler |
| GB0410712D0 (en) | 2004-05-13 | 2004-06-16 | Novartis Ag | Organic compounds |
| EP1790650B1 (en) * | 2004-08-31 | 2014-03-26 | Msd Kk | NEW SUBSTITUTED IMIDAZOLE DERIVATIVES |
| EP1804801A2 (en) * | 2004-10-15 | 2007-07-11 | Biogen Idec MA, Inc. | Methods of treating vascular injuries |
| DOP2006000051A (es) * | 2005-02-24 | 2006-08-31 | Lilly Co Eli | Inhibidores de vegf-r2 y métodos |
| HRP20150642T1 (hr) | 2006-12-22 | 2015-08-14 | Astex Therapeutics Limited | BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a |
-
2008
- 2008-10-15 KR KR1020107010615A patent/KR20100076022A/ko not_active Withdrawn
- 2008-10-15 BR BRPI0817434-2A patent/BRPI0817434A2/pt not_active IP Right Cessation
- 2008-10-15 EP EP08838625A patent/EP2212323B1/en active Active
- 2008-10-15 AR ARP080104492A patent/AR068877A1/es unknown
- 2008-10-15 EA EA201000615A patent/EA201000615A1/ru unknown
- 2008-10-15 PL PL08838625T patent/PL2212323T3/pl unknown
- 2008-10-15 US US12/679,549 patent/US8367662B2/en not_active Expired - Fee Related
- 2008-10-15 PE PE2008001769A patent/PE20091383A1/es not_active Application Discontinuation
- 2008-10-15 MX MX2010004244A patent/MX2010004244A/es active IP Right Grant
- 2008-10-15 JP JP2010529359A patent/JP5456681B2/ja not_active Expired - Fee Related
- 2008-10-15 CN CN2008801122032A patent/CN101827844B/zh not_active Expired - Fee Related
- 2008-10-15 WO PCT/EP2008/063841 patent/WO2009050183A2/en not_active Ceased
- 2008-10-15 ES ES08838625T patent/ES2393430T3/es active Active
- 2008-10-15 PT PT08838625T patent/PT2212323E/pt unknown
- 2008-10-15 CA CA2703037A patent/CA2703037A1/en not_active Abandoned
- 2008-10-15 AU AU2008313773A patent/AU2008313773B2/en not_active Ceased
- 2008-10-16 TW TW097139735A patent/TW200922570A/zh unknown
- 2008-10-16 CL CL2008003056A patent/CL2008003056A1/es unknown
-
2010
- 2010-03-25 IL IL204720A patent/IL204720A0/en unknown
- 2010-04-01 ZA ZA2010/02334A patent/ZA201002334B/en unknown
- 2010-04-08 MA MA32756A patent/MA31766B1/fr unknown
- 2010-04-16 TN TN2010000167A patent/TN2010000167A1/fr unknown
- 2010-05-11 CO CO10056124A patent/CO6270321A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US8367662B2 (en) | 2013-02-05 |
| BRPI0817434A2 (pt) | 2015-06-16 |
| TN2010000167A1 (en) | 2011-11-11 |
| JP2011500623A (ja) | 2011-01-06 |
| AU2008313773A1 (en) | 2009-04-23 |
| CN101827844B (zh) | 2013-08-14 |
| CL2008003056A1 (es) | 2009-07-31 |
| CO6270321A2 (es) | 2011-04-20 |
| EP2212323A2 (en) | 2010-08-04 |
| IL204720A0 (en) | 2010-11-30 |
| PE20091383A1 (es) | 2009-10-17 |
| AU2008313773A8 (en) | 2010-04-29 |
| KR20100076022A (ko) | 2010-07-05 |
| TW200922570A (en) | 2009-06-01 |
| CA2703037A1 (en) | 2009-04-23 |
| AU2008313773B2 (en) | 2012-04-12 |
| PL2212323T3 (pl) | 2013-01-31 |
| WO2009050183A2 (en) | 2009-04-23 |
| EP2212323B1 (en) | 2012-08-15 |
| ZA201002334B (en) | 2011-03-30 |
| MX2010004244A (es) | 2010-04-30 |
| JP5456681B2 (ja) | 2014-04-02 |
| ES2393430T3 (es) | 2012-12-21 |
| EA201000615A1 (ru) | 2010-12-30 |
| PT2212323E (pt) | 2012-11-27 |
| WO2009050183A3 (en) | 2009-07-16 |
| US20100210641A1 (en) | 2010-08-19 |
| MA31766B1 (fr) | 2010-10-01 |
| CN101827844A (zh) | 2010-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR068877A1 (es) | Derivados heterociclicos de imidazol | |
| CO5251463A1 (es) | Compuestos heterociclicos y composicion farmaceutica que coniene dichos compuestos | |
| AR053405A1 (es) | Derivados de urea sustituidas, composiciones farmaceuticas y metodos para el tratamiento de cardiopatias | |
| AR053728A1 (es) | Pirimidinas condensadas como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia y composiciones farmaceuticas que las contienen en combinacion con otros agentes terapeuticos | |
| AR063800A1 (es) | Derivados de acido nicotinico, composiciones farmaceuticas que las contienen y metodos de uso de los mismos | |
| PE20231190A1 (es) | Degradadores de moleculas pequenas de piperidinilo de helios y procedimientos de uso | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| NO20064309L (no) | Azabicyklo(3.1.0)heksanderivater anvendelige som modulatorer for dopamin D3 receptorer | |
| JP2018510857A (ja) | ＴＧＦ−β阻害剤 | |
| AR044614A1 (es) | Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4) | |
| AR074862A1 (es) | Derivados de heterociclo biciclicos y sus metodos de uso | |
| MY151080A (en) | Viral polymerase inhibitors | |
| AR070521A1 (es) | Derivados de 4h-pirido[4,3-d]-pirimidin-4-ona,inhibidores de quinasas,composiciones farmaceuticas que los contienen,uso de los mismos para el tratamiento de enfermedades con proliferacion celular o autoinmunes y metodo de preparacion de intermediarios de sintesis . | |
| AR042532A1 (es) | Compuestos de 5,8-dihidro-6h-pirido[2,3-d]pirimidin-7-ona | |
| JP6789941B2 (ja) | Ｔｇｆ−ベータ阻害剤としての縮合イミダゾール誘導体 | |
| AR065811A1 (es) | Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos. | |
| AR062785A1 (es) | Compuestos de 4-metilpiridopirimidinona, composiciones farmaceuticas que los contienen y usos en estados patologicos asociados al crecimiento anormal celular,tal como cancer. | |
| HRP20241681T1 (hr) | Spojevi za modulaciju androgenskih receptora | |
| PE20090630A1 (es) | Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion | |
| AR051469A1 (es) | Derivados de indol tetraciclicos como agentes antiviricos | |
| AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
| AR066121A1 (es) | Derivados de pirimidinona y metodos para su uso | |
| AR064414A1 (es) | Derivados de 1-azoniabiciclo[2, 2, 2]octano y 1-azabiciclo[2, 2, 2]oct-3-ilo, un proceso para su preparacion, una composicion farmaceutica que los comprende, procedimiento de obtencion de la misma, su uso en la elaboracion de un medicamento para el tratamiento de epoc y un producto farmaceutico que | |
| AR123355A1 (es) | Inhibidores de apol1 y métodos para usar los mismos | |
| AR036905A1 (es) | Derivados del 3-azabiciclo[3.1.0]hexano, composiciones farmaceuticas que los contienen, su uso en un metodo para tratar un trastorno o afeccion en un mamifero, e intermediarios utiles para su sintesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |